Your browser doesn't support javascript.
loading
Treatment approaches in autoimmune pancreatitis (Review).
Padureanu, Vlad; Dragoescu, Alice Nicoleta; Padureanu, Rodica; Rosu, Maria Magdalena; Radulescu, Dumitru; Dop, Dalia; For Ofoiu, Mircea Catalin.
Afiliación
  • Padureanu V; Department of Internal Medicine, University of Medicine and Pharmacy of Craiova, 200349 Craiova, Romania.
  • Dragoescu AN; Department of Anaesthesiology and Intensive Care, University of Medicine and Pharmacy of Craiova, 200349 Craiova, Romania.
  • Padureanu R; Department of Internal Medicine, University of Medicine and Pharmacy of Craiova, 200349 Craiova, Romania.
  • Rosu MM; Department of Diabetes, Nutrition and Metabolic Diseases, County Clinical Emergency Hospital of Craiova, Craiova 200642, Romania.
  • Radulescu D; Department of Pediatrics, University of Medicine and Pharmacy of Craiova, 200349 Craiova, Romania.
  • Dop D; Department of Surgery, University of Medicine and Pharmacy of Craiova, 200349 Craiova, Romania.
  • For Ofoiu MC; Department of Internal Medicine, University of Medicine and Pharmacy of Craiova, 200349 Craiova, Romania.
Biomed Rep ; 20(2): 26, 2024 Feb.
Article en En | MEDLINE | ID: mdl-38259589
ABSTRACT
Autoimmune pancreatitis (AIP) is a rare disease. There are two distinct types of AIP AIP type 1 (AIP-1), a pancreatic manifestation of a multi-organ disease linked to immunoglobulin (Ig)G4, and AIP type 2 (AIP-2), a pancreas-specific disease unrelated to IgG4. The usual course of treatment for AIP is oral corticosteroid medication. Rituximab has also been recommended for recurrent AIP-1 in order to initiate remission and provide ongoing treatment. Immunomodulators such as azathioprine are used to keep certain patients in remission. Evaluation also takes into account a number of pharmacological alternatives, including biologic drugs like anti-tumor necrosis factor therapy, a safe and efficient second-line treatment for AIP-2 relapse or steroid dependence. Corticosteroids and immunosuppressants, which are poorly tolerated due to considerable side effects, are being replaced by other biologic drugs, which may offer a beneficial therapeutic alternative.
Palabras clave
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Idioma: En Revista: Biomed Rep Año: 2024 Tipo del documento: Article País de afiliación: Rumanía Pais de publicación: Reino Unido
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Idioma: En Revista: Biomed Rep Año: 2024 Tipo del documento: Article País de afiliación: Rumanía Pais de publicación: Reino Unido